Basic Information
IcanoMAB is a private biotechnology company dedicated to preclinical and the development of precise canonical antibodies for the treatment of cancer, immune system-related diseases, and Covid-19. The company is developing its proprietary clinical candidates to pioneer novel approaches for improving clinical outcomes in immuno-oncology, solid tumors, as well as immunology and inflammation.IcanoMAB was founded by experienced entrepreneurs and scientists with a successful track record of drug development across multiple companies, including Boehringer Mannheim, Roche, MAB Discovery, Xantos Biomedicine, JSB Partners, Novartis, and TVM Capital Life Science.